MiMedx Q1 net sales $71.7M (+21.7% YoY); net loss narrows to $5.0M; Adj. EBITDA $5.5M

MIMEDX GROUP, INC.

2023-Q1 EPS reported -$0.06 revenue$71,676,000

Net sales $71.7M in Q1 2023, up 21.7% from $58.9M in Q1 2022.
Net loss improved to $5.0M from $10.5M in prior year; Adjusted EBITDA of $5.5M.
CEO attributed growth to robust demand for new surgical products and accelerated growth in private physician offices.
Gross margin improved sequentially; operating expenses grew slower than sales.
Company also announced an upcoming Chief Financial Officer transition.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MIMEDX GROUP, INC. reported first quarter 2023 results: revenue $71.7 million, net income net loss of $5.0 million.

Period: first quarter 2023
Revenue: $71.7 million
Net income: net loss of $5.0 million
Result: reported results

Exact text from the filing

announced operating and financial results for the first quarter 2023, which ended March 31, 2023, including net sales of $71.7 million, net loss of $5.0 million

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-132450

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.